tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Jan 26;10(2):193.
doi: 10.3390/vaccines10020193.
Comparing SARS-CoV-2 Antibody Responses after Various COVID-19 Vaccinations in Healthcare Workers
Yu-Kyung Kim[SUP] 1 [/SUP], Dohsik Minn[SUP] 2 [/SUP], Soon-Hee Chang[SUP] 1 [/SUP], Jang-Soo Suh[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) vaccination began for healthcare workers in South Korea at the end of February 2021. This study investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses after various COVID-19 vaccinations in healthcare workers. Blood specimens of 497 vaccinated healthcare workers were collected. Inoculated vaccines were ChAdOx1 (AstraZeneca/Oxford), BNT162b2 (Pfizer/BioNTech), JNJ-78436735 (Janssen), and mRNA-1273 (Moderna). Each specimen was tested for antibodies against SARS-CoV-2 using Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics), SARS-CoV-2 IgG II Quant assay (Abbott), and R-FIND SARS-CoV-2 Neutralizing Antibody kit (SG medical Inc.). A questionnaire was used to investigate adverse events related to vaccination. We found that 99.5% of the subjects showed a 96-100% positive rate in all three antibody assays, regardless of the vaccine type. The antibody-positive rate of completed vaccination groups reached 96-100%, and antibody quantities significantly increased 2 weeks after vaccination. The antibody values measured approximately 3 months after BNT162b2 inoculation significantly correlated with adverse events.
Keywords: Abbott SARS-CoV-2 IgG II Quant assay; AstraZeneca-Oxford; COVID-19 vaccine; Elecsys Anti-SARS-CoV-2 S assay; Pfizer-BioNTech; neutralizing antibody.
. 2022 Jan 26;10(2):193.
doi: 10.3390/vaccines10020193.
Comparing SARS-CoV-2 Antibody Responses after Various COVID-19 Vaccinations in Healthcare Workers
Yu-Kyung Kim[SUP] 1 [/SUP], Dohsik Minn[SUP] 2 [/SUP], Soon-Hee Chang[SUP] 1 [/SUP], Jang-Soo Suh[SUP] 1 [/SUP]
Affiliations
- PMID: 35214652
- DOI: 10.3390/vaccines10020193
Abstract
Coronavirus disease 2019 (COVID-19) vaccination began for healthcare workers in South Korea at the end of February 2021. This study investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses after various COVID-19 vaccinations in healthcare workers. Blood specimens of 497 vaccinated healthcare workers were collected. Inoculated vaccines were ChAdOx1 (AstraZeneca/Oxford), BNT162b2 (Pfizer/BioNTech), JNJ-78436735 (Janssen), and mRNA-1273 (Moderna). Each specimen was tested for antibodies against SARS-CoV-2 using Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics), SARS-CoV-2 IgG II Quant assay (Abbott), and R-FIND SARS-CoV-2 Neutralizing Antibody kit (SG medical Inc.). A questionnaire was used to investigate adverse events related to vaccination. We found that 99.5% of the subjects showed a 96-100% positive rate in all three antibody assays, regardless of the vaccine type. The antibody-positive rate of completed vaccination groups reached 96-100%, and antibody quantities significantly increased 2 weeks after vaccination. The antibody values measured approximately 3 months after BNT162b2 inoculation significantly correlated with adverse events.
Keywords: Abbott SARS-CoV-2 IgG II Quant assay; AstraZeneca-Oxford; COVID-19 vaccine; Elecsys Anti-SARS-CoV-2 S assay; Pfizer-BioNTech; neutralizing antibody.